Express News | Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary

BenzingaJul 22 08:17 ET

Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out

Cassava Sciences (SAVA) shares were up nearly 24% in recent Monday trading after its recently appointed chairman told shareholders the biotech was expecting the first phase 3 trial read out of

MT Newswires14:39 ET

Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials

On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees.He said the company is in the final stages of testing its Alzheimer'

Benzinga14:03 ET

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday's session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell

Benzinga13:28 ET

IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-

BenzingaJul 22 11:28 ET

Why Cassava Sciences Stock Is Skyrocketing Today

Yahoo FinanceJul 22 11:27 ET